Goldman Sachs ActiveBeta Europe Equity ETF
GSEU - ETF AI Analysis
Top Page
Goldman Sachs ActiveBeta Europe Equity ETF (GSEU)
GSEU, the Goldman Sachs ActiveBeta Europe Equity ETF, has a solid overall rating driven mainly by high-quality European leaders like Novartis, HSBC, and AstraZeneca, which show strong financial performance, positive earnings outlooks, and generally supportive valuations. These strengths are partly offset by holdings such as Shell and SAP, where weaker technical trends, growth challenges, or valuation concerns introduce some risk. The fund is also notably exposed to large European financials and healthcare names, so sector and regional concentration are key risk factors to keep in mind.
GSEU vs. SPDR S&P 500 ETF (SPY)
- AUM
- 173.95M
- Region
- Europe
- Expense Ratio
- 0.25%
- Beta
- 0.65
- Issuer
- Goldman Sachs
- Inception Date
- Mar 02, 2016
- Dividend Yield
- 2.73%
- Asset Class
- Equity
- Index Tracked
- Goldman Sachs ActiveBeta Europe Equity
GSEU Summary
GSEU is the Goldman Sachs ActiveBeta Europe Equity ETF, which follows the Goldman Sachs ActiveBeta Europe Equity index and invests in a wide range of European stocks. It holds companies from many countries and sectors, including well-known names like ASML, Nestlé, HSBC, and Shell. This fund aims to give you broad, diversified exposure to Europe in a single investment, which can be useful if you want long-term growth and don’t want to pick individual European stocks. A key risk is that it can rise or fall with European stock markets, so its value may swing over time.
How much will it cost me?
This ETF has an annual expense ratio of 0.25%, which means you’ll pay about $2.50 per year for every $1,000 you invest. That’s slightly higher than many plain-vanilla index ETFs because it uses Goldman Sachs’ ActiveBeta strategy to actively tilt toward factors like value, momentum, quality, and low volatility.
What would affect this ETF?
This ETF focuses on developed European stocks across many sectors, so it could benefit if Europe’s economy strengthens, interest rates fall, and large holdings in technology, health care, and financials like ASML, Roche, and HSBC perform well. On the other hand, it could be hurt by slower European growth, higher interest rates, banking or energy sector troubles, or political and regulatory changes in Europe that weigh on broad stock markets.
GSEU Top 10 Holdings
GSEU leans heavily into Europe’s blue-chip health care and financial names, with a tech twist. Drugmakers like Novartis, Roche, and AstraZeneca have been quietly rising, giving the fund a steady backbone, while consumer giant Nestlé adds a defensive cushion. On the other side, ASML has lost some momentum lately, and banks such as HSBC and Banco Santander are dragging performance, reflecting mixed sentiment toward European financials. With holdings spread across the U.K., Switzerland, Germany, Spain, and the Netherlands, this ETF is a diversified bet on developed Europe rather than a single-country story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 3.69% | $6.31M | EUR 519.88B | 53.49% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 2.01% | $3.44M | CHF 246.17B | 31.59% | 80Outperform |
 GB:HSBA | HSBC Holdings | 1.83% | $3.13M | GBP 229.76B | 23.18% | 80Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 GB:SHEL | Shell (UK) | 1.63% | $2.78M | GBP 205.39B | 26.31% | 73Outperform |
 DE:SAP | SAP SE | 1.27% | $2.18M | EUR 245.13B | -2.91% | 66Neutral |
 CH:NESN | Nestlé SA | 1.27% | $2.17M | CHF 222.27B | 8.80% | 71Outperform |
 ES:SAN | Banco Santander | 1.24% | $2.12M | EUR 163.67B | 22.69% | 73Outperform |
 DE:SIE | Siemens | 1.18% | $2.01M | EUR 206.99B | 10.52% | 74Outperform |
GSEU Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GSEU, the sentiment is Positive. The current price of 49.35 is above the 20-day moving average (MA) of 48.17, above the 50-day MA of 48.36, and above the 200-day MA of 47.72, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 58.09 is Neutral, neither overbought nor oversold. The STOCH value of 66.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GSEU.
GSEU Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| GSEU | $49.35 | $51.00(3.34% Upside) | $173.95M | 0.25% | 62Neutral |
 VGK | $89.65 | $106.04(18.28% Upside) | $30.41B | 0.06% | 61Neutral |
 IEUR | $76.13 | $89.23(17.20% Upside) | $9.84B | 0.09% | 63Neutral |
 DBEU | $55.45 | $64.98(17.19% Upside) | $798.04M | 0.46% | 64Neutral |
 SPEU | $55.38 | $64.64(16.72% Upside) | $716.83M | 0.07% | 62Neutral |
 FLEE | $39.08 | $45.64(16.78% Upside) | $101.23M | 0.09% | 63Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GSEU | Goldman Sachs ActiveBeta Europe Equity ETF | 49.35 | 5.86 | 13.47% | |
| VGK | Vanguard FTSE Europe ETF | 89.65 | 9.82 | 12.30% | |
| IEUR | iShares Core MSCI Europe ETF | 76.13 | 8.17 | 12.03% | |
| DBEU | Xtrackers MSCI Europe Hedged Equity ETF | 55.45 | 7.81 | 16.40% | |
| SPEU | SPDR Portfolio Europe ETF | 55.38 | 5.91 | 11.94% | |
| FLEE | Franklin FTSE Europe ETF | 39.08 | 4.18 | 11.99% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.